homovanillic acid has been researched along with Delayed Effects, Prenatal Exposure in 31 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, the exposure to new environmental condition elevated blood corticosterone levels and enhanced behavioral activities to a greater extent in the Dex group than in controls at 7 wk of life, suggesting that elevated glucocorticoid levels during the pregnancy mimicked prenatal mild stress, producing developmental alterations in brain monoamine metabolism, endocrine response, and behavior in adult offspring." | 3.69 | Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring. ( Kamei, K; Kitera, K; Mikuni, M; Muneoka, K; Ogawa, T; Takahashi, K; Takigawa, M, 1997) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | 1.62 | Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors. ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| " Acute or chronic administration of methamphetamine elevates the levels of the extracellular monoamine neurotransmitters, such as dopamine." | 1.35 | Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. ( Bubenikova-Valesova, V; Hruba, L; Janovsky, M; Kacer, P; Rambousek, L; Schutova, B; Slamberova, R; Syslova, K, 2009) |
| "Styrene was evaluated to determine its neurochemical effects in the offspring of rats exposed during the gestation period." | 1.30 | Effects of prenatal exposure to styrene on neurochemical levels in rat brain. ( Ikeda, T; Katakura, Y; Kishi, R; Miyake, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.45) | 18.7374 |
| 1990's | 11 (35.48) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Koizumi, H | 1 |
| Hiraga, T | 1 |
| Oharomari, LK | 1 |
| Hata, T | 1 |
| Shima, T | 1 |
| Yook, JS | 1 |
| Okamoto, M | 1 |
| Mouri, A | 1 |
| Nabeshima, T | 1 |
| Soya, H | 1 |
| Rose, KM | 1 |
| Parmar, MS | 1 |
| Cavanaugh, JE | 1 |
| Winter, C | 1 |
| Djodari-Irani, A | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Feldon, J | 1 |
| Juckel, G | 1 |
| Meyer, U | 1 |
| Yokota, S | 1 |
| Mizuo, K | 1 |
| Moriya, N | 1 |
| Oshio, S | 1 |
| Sugawara, I | 1 |
| Takeda, K | 1 |
| Tekes, K | 1 |
| Gyenge, M | 1 |
| Hantos, M | 1 |
| Csaba, G | 1 |
| Ling, Z | 2 |
| Zhu, Y | 1 |
| Tong, CW | 1 |
| Snyder, JA | 1 |
| Lipton, JW | 1 |
| Carvey, PM | 2 |
| Wang, S | 1 |
| Yan, JY | 1 |
| Lo, YK | 1 |
| Bubenikova-Valesova, V | 1 |
| Kacer, P | 1 |
| Syslova, K | 1 |
| Rambousek, L | 1 |
| Janovsky, M | 1 |
| Schutova, B | 1 |
| Hruba, L | 1 |
| Slamberova, R | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Hamilton, LR | 1 |
| Czoty, PW | 1 |
| Nader, MA | 1 |
| Phillips, PE | 1 |
| Johns, JM | 1 |
| Lubin, DA | 1 |
| Budygin, EA | 1 |
| Gainetdinov, RR | 1 |
| Lieberman, JA | 1 |
| Wightman, RM | 1 |
| Galineau, L | 1 |
| Belzung, C | 1 |
| Kodas, E | 1 |
| Bodard, S | 1 |
| Guilloteau, D | 1 |
| Chalon, S | 1 |
| Aldridge, JE | 1 |
| Meyer, A | 1 |
| Seidler, FJ | 2 |
| Slotkin, TA | 2 |
| Kreider, ML | 1 |
| Tate, CA | 1 |
| Yim, AJ | 1 |
| Miranda-Paiva, CM | 1 |
| Flório, JC | 1 |
| Oliveira, CA | 1 |
| Nasello, AG | 1 |
| Felicio, LF | 1 |
| Wang, CT | 1 |
| Shui, HA | 1 |
| Huang, RL | 1 |
| Tai, MY | 1 |
| Peng, MT | 1 |
| Tsai, YF | 1 |
| Romero, E | 1 |
| Guaza, C | 1 |
| Castellano, B | 1 |
| Borrell, J | 1 |
| Pérez-Otaño, I | 2 |
| Luquin, MR | 2 |
| Oset, C | 2 |
| Herrero, MT | 1 |
| Kupsch, A | 2 |
| Oertel, W | 2 |
| Obeso, JA | 2 |
| Del Río, J | 2 |
| Alonso, SJ | 1 |
| Navarro, E | 1 |
| Rodriguez, M | 1 |
| Needlman, R | 1 |
| Zuckerman, B | 1 |
| Anderson, GM | 1 |
| Mirochnick, M | 1 |
| Cohen, DJ | 1 |
| Silva-Araújo, A | 1 |
| Silva, MC | 1 |
| Simon, A | 1 |
| Nguyen-Legros, J | 1 |
| Ali, SF | 1 |
| Tavares, MA | 1 |
| Muneoka, K | 1 |
| Mikuni, M | 1 |
| Ogawa, T | 1 |
| Kitera, K | 1 |
| Kamei, K | 1 |
| Takigawa, M | 1 |
| Takahashi, K | 1 |
| Watanabe, M | 1 |
| Nonaka, R | 1 |
| Hagino, Y | 1 |
| Kodama, Y | 1 |
| Schneider, ML | 1 |
| Clarke, AS | 1 |
| Kraemer, GW | 1 |
| Roughton, EC | 1 |
| Lubach, GR | 1 |
| Rimm-Kaufman, S | 1 |
| Schmidt, D | 1 |
| Ebert, M | 1 |
| Katakura, Y | 1 |
| Kishi, R | 1 |
| Ikeda, T | 1 |
| Miyake, H | 1 |
| Du, W | 1 |
| Aloyo, VJ | 1 |
| Pazdelski, PS | 1 |
| Harvey, JA | 1 |
| Won, L | 1 |
| Bubula, N | 1 |
| Heller, A | 1 |
| Trinidad Herrero, M | 1 |
| Chiavegatto, S | 1 |
| Bernardi, MM | 1 |
| Rathbun, W | 1 |
| Druse, MJ | 1 |
| Guilarte, TR | 1 |
| Wagner, HN | 1 |
| Frost, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
31 other studies available for homovanillic acid and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2021 |
Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dietary Supplements; Disease Models, Anima | 2014 |
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Diseases; Chromatography, High Press | 2009 |
Effect of prenatal exposure to diesel exhaust on dopaminergic system in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Circadian Rhythm; Dopamine; Female; Homovanillic Aci | 2009 |
Transgenerational hormonal imprinting caused by vitamin A and vitamin D treatment of newborn rats. Alterations in the biogenic amine contents of the adult brain.
Topics: Animals; Animals, Newborn; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Hydroxyindoleacetic | 2009 |
Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; Analysis of Variance; Animals; Body Weight; Brai | 2009 |
Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide.
Topics: Amygdala; Animals; Brain; Corpus Striatum; Dopamine; Female; Frontal Lobe; Hippocampus; Homovanillic | 2009 |
Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Mod | 2009 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Behavioral characterization of adult male and female rhesus monkeys exposed to cocaine throughout gestation.
Topics: Animals; Behavior, Animal; Cocaine; Conditioning, Psychological; Female; Homovanillic Acid; Hydroxyi | 2011 |
Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoreceptors; Cocaine; Corpus Striatum; Dopamine; Dopamine | 2003 |
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Age Fac | 2005 |
Alterations in central nervous system serotonergic and dopaminergic synaptic activity in adulthood after prenatal or neonatal chlorpyrifos exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Brain; Chlorpyrifos; Dopamine; Female; Ho | 2005 |
Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Developmental Disabilities; Dexamethasone; Dopamine; | 2006 |
A comparative study of morphine treatment regimen prior to mating and during late pregnancy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain | 2006 |
Sexual motivation is demasculinized, but not feminized, in prenatally stressed male rats.
Topics: Animals; Copulation; Dopamine; Female; Homovanillic Acid; Immobilization; Male; Motivation; Pregnanc | 2006 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; An | 2010 |
Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callithrix; Dopamine; Enkephalin, Methionine; Female | 1995 |
Permanent dopaminergic alterations in the n. accumbens after prenatal stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Female; Functional Laterality; H | 1994 |
Cerebrospinal fluid monoamine precursors and metabolites in human neonates following in utero cocaine exposure: a preliminary study.
Topics: Biogenic Monoamines; Brain; Case-Control Studies; Cocaine; Dopamine; Dose-Response Relationship, Dru | 1993 |
The effects of prenatal exposure to cocaine on the dopaminergic cells in the rat retina. An immunocytochemical and neurochemical study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Female; Homo | 1996 |
Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Cortex; Aging; Analysis of Variance; Animals; Biogenic Monoa | 1997 |
Effects of prenatal methylazoxymethanol treatment on striatal dopaminergic systems in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain; Carrier Proteins; Corpus Striatum; | 1998 |
Prenatal stress alters brain biogenic amine levels in primates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Behavior, Animal; Biogenic Amines; Brain; Female; Ho | 1998 |
Effects of prenatal exposure to styrene on neurochemical levels in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Birth Weight; Brain; Brain Chemistry; Dop | 1999 |
Effects of prenatal cocaine exposure on amphetamine-induced dopamine release in the caudate nucleus of the adult rabbit.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Caudate Nucleus; Cocaine; Dopamine; Dopamine U | 1999 |
Fetal exposure to methamphetamine in utero stimulates development of serotonergic neurons in three-dimensional reaggregate tissue culture.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Brain; Cell Aggregation; Cel | 2002 |
Neurotoxic effect of prenatal exposure to MPTP on the dopaminergic systems of the marmoset brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adolescent; Animals; C | 1992 |
Effects of prenatal diphenhydramine exposure on dopaminergic function in adult rats.
Topics: Animals; Apomorphine; Copulation; Corpus Striatum; Diphenhydramine; Dopamine; Female; Homovanillic A | 1991 |
Dopamine, serotonin, and acid metabolites in brain regions from the developing offspring of ethanol-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liqui | 1985 |
Effects of perinatal vitamin B6 deficiency on dopaminergic neurochemistry.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Chromatography, High Pressure Liquid; Corpus S | 1987 |